-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the characteristics of a non-GLP toxicology platform?
Author:
InnoModels
Release time:
2024-03-14
Toxicology research plays a crucial role in drug discovery, biotechnology, and various research programs. It is able to assess the potential hazards of chemicals, drugs, environmental pollutants, etc. to the human body or the ecosystem. However, traditional GLP (Good Laboratory Practice) toxicology platforms are often limited by strict regulations, complex operational procedures and high costs. The non-GLP toxicology platform launched by InnoModels Biotechnology, with its unique advantages, has revolutionized the field of scientific research and drug discovery.
Flexibility and Efficiency
The biggest advantage of InnoModels' non-GLP toxicology platform is its high flexibility and efficiency. Compared to traditional GLP platforms, non-GLP platforms do not need to comply with stringent regulatory requirements, which greatly simplifies the operational process and approval procedures. This means that researchers can conduct experiments more quickly, shortening the R&D cycle and improving research efficiency.
Cost-effectiveness
Cost is a key factor constraining many research projects and drug development. InnoModels' non-GLP toxicology platform has significant advantages in cost control. Since there is no need to follow GLP standards, the platform can save a lot of costs on compliance audits, laboratory construction and equipment purchases. This makes high-quality toxicology research affordable for more research institutions and companies.

Customized Services
InnoModels Bio's non-GLP toxicology platform also provides personalized and customized services. According to the specific needs and experimental requirements of customers, the platform can provide customers with tailor-made experimental programs, data analysis and interpretation and other services. This customized service can better meet the scientific research needs of customers and improve the relevance and effectiveness of experiments.
Rapid Response and Innovation
In the rapidly developing field of scientific research and drug discovery, rapid response and innovation capability are crucial. InnoModels Bio's non-GLP toxicology platform has strong rapid response and innovation capabilities. The platform can quickly adapt to new research needs and technological development, providing customers with the latest and most effective toxicology research methods and technical support.
Wide range of applications
InnoModels Bio's non-GLP toxicology platform is not only suitable for drug research and development, but also widely used in cosmetics, food, environmental protection and other fields. The platform can provide customers with comprehensive toxicology evaluation services to help them understand the safety, stability and potential risks of their products.
In summary, InnoModels' non-GLP toxicology platform has injected new momentum into the field of scientific research and drug discovery with its advantages of flexibility, cost-effectiveness, customized services, rapid response and innovation capabilities, and a wide range of applications. In the future, with the continuous progress of science and technology and the growing demand for scientific research, we have reason to believe that the non-GLP toxicology platform of InnoModels Biotechnology will play an even more important role in promoting scientific research and innovation as well as drug discovery and development.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd